{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:09:17Z","timestamp":1778098157990,"version":"3.51.4"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012628","name":"Japan Epilepsy Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Progressive encephalomyelitis with rigidity and myoclonus (PERM) is a severe form of stiff-person spectrum disorder characterized by painful spasms, myoclonic jerks, hyperekplexia, brainstem dysfunction, and dysautonomia, which is sometimes resistant to \u03b3-amino-butyric acid (GABA)-ergic agents. The response to immunotherapy varies depending on identified autoantibodies. We report a dramatic response to dexmedetomidine in a patient with glycine receptor (GlyR) antibody-positive PERM who developed intractable clusters of myoclonic jerks and paroxysmal sympathetic hyperactivity (PSH) that was highly refractory to conventional symptomatic treatment with GABAergic drugs and immunotherapy.<\/jats:p><jats:p><jats:bold>Case Presentation:<\/jats:bold> A 62-year-old Japanese man was transferred to our center for intermittent painful spasms that progressed in severity over the preceding 7 weeks. On admission, he had gaze-evoked nystagmus, and paroxysmal painful spasms\/myoclonic jerks triggered by sound or touch. The myoclonic jerks rapidly worsened, along with the development of hyperekplexia, opisthotonus, and PSH, leading to prolonged apnea requiring mechanical ventilation. Brain and spinal cord magnetic resonance imaging was unremarkable. Cerebrospinal fluid (CSF) examination revealed mild pleocytosis and oligoclonal bands. Surface electromyography confirmed simultaneous agonist-antagonist continuous motor unit activity. Based on the clinico-electrophysiological features, PERM was suspected. He was initially treated with intravenous steroids, immunoglobulin, benzodiazepines, and propofol, but the symptoms persisted. On day 9, he received a continuous infusion of dexmedetomidine, which resulted in dramatic reduction in the frequency of clusters of myoclonic jerks and PSH. The effect of dexmedetomidine was confirmed by surface electromyography. The addition of plasma exchange resulted in further clinical improvement. GlyR antibodies were identified in the CSF but not the serum, leading to the diagnosis of GlyR antibody-positive PERM.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> PERM is an immune-mediated disorder, but dexmedetomidine, a highly selective \u03b12-adrenergic agonist, may alleviate paroxysmal symptoms by decreasing noradrenergic neuronal activity, resulting in attenuation of antibody-mediated disinhibited increased motor and sympathetic activity. Dexmedetomidine may be useful as an adjunctive symptomatic therapy in PERM and related disorders.<\/jats:p>","DOI":"10.3389\/fneur.2021.703050","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T05:08:20Z","timestamp":1626066500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case Report: Dexmedetomidine for Intractable Clusters of Myoclonic Jerks and Paroxysmal Sympathetic Hyperactivity in Progressive Encephalomyelitis With Rigidity and Myoclonus"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuzo","family":"Fujino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonz\u00e1lez","year":"2014","journal-title":"Brain."},{"key":"B3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/WCO.0000000000000450","article-title":"Redefining progressive encephalomyelitis with rigidity and myoclonus after the discovery of antibodies to glycine receptors","volume":"30","author":"Crisp","year":"2017","journal-title":"Curr Opin Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"71420","DOI":"10.1001\/jamaneurol.2016.0133","article-title":"Clinical and immunologic investigations in patients with stiff-person spectrum disorder","volume":"73","author":"Martinez-Hernandez","year":"2016","journal-title":"JAMA Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1212\/01.wnl.0000327606.50322.f0","article-title":"Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody","volume":"71","author":"Hutchinson","year":"2008","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1093\/brain\/awz297","article-title":"Glycine receptor autoantibodies disrupt inhibitory neurotransmission","volume":"142","author":"Crisp","year":"2019","journal-title":"Brain."},{"key":"B7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/archneurol.2011.991","article-title":"Stiff-man syndrome and variants: clinical course, treatments, and outcomes","volume":"69","author":"McKeon","year":"2012","journal-title":"Arch Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1212\/01.wnl.0000284606.00074.f1","article-title":"Unexpected benefit of propofol in stiff-person syndrome","volume":"70","author":"Hattan","year":"2008","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF00315688","article-title":"Sudden death and paroxysmal autonomic dysfunction in stiff-man syndrome","volume":"238","author":"Mitsumoto","year":"1991","journal-title":"J Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1474-4422(17)30259-4","article-title":"Paroxysmal sympathetic hyperactivity: the storm after acute brain injury","volume":"16","author":"Meyfroidt","year":"2017","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.17659\/01.2019.0062","article-title":"Successful management of paroxysmal sympathetic hyperactivity in anti-N-methyl-D-aspartate receptor encephalitis","volume":"9","author":"Jing","year":"2019","journal-title":"JCR."},{"key":"B12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mehy.2007.04.037","article-title":"The excitatory:inhibitory ratio model (EIR model): An integrative explanation of acute autonomic overactivity syndromes","volume":"70","author":"Baguley","year":"2008","journal-title":"Med Hypotheses."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40265-015-0419-5","article-title":"Dexmedetomidine: a review of its use for sedation in the intensive care setting","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejphar.2011.08.012","article-title":"Inhibitory effect of glutamate release from rat cerebrocortical nerve terminals by \u03b12 adrenoceptor agonist dexmedetomidine","volume":"670","author":"Chiu","year":"2011","journal-title":"Eur J Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.05.021","article-title":"Dexmedetomidine increases the activity of excitatory amino acid transporter type 3 expressed in Xenopus oocytes: the involvement of protein kinase C and phosphatidylinositol 3-kinase","volume":"738","author":"Do","year":"2014","journal-title":"Eur J Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/00000542-200008000-00016","article-title":"The effects of increasing plasma concentrations of dexmedetomidine in humans","volume":"93","author":"Ebert","year":"2000","journal-title":"Anesthesiology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"116993","DOI":"10.1016\/j.jns.2020.116993","article-title":"Therapeutic considerations in a case of progressive encephalomyelitis with rigidity and myoclonus","volume":"416","author":"Gluck","year":"2020","journal-title":"J Neurol Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12028-007-0066-0","article-title":"Dexmedetomidine for the treatment of paroxysmal autonomic instability with dystonia","volume":"7","author":"Goddeau","year":"2007","journal-title":"Neurocrit Care."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.703050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T05:08:23Z","timestamp":1626066503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.703050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":18,"alternative-id":["10.3389\/fneur.2021.703050"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.703050","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"article-number":"703050"}}